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Over recent years, there has been a great deal of interest in the prospects of stem cell-based therapies for the
treatment of nervous system disorders. The eagerness of scientists, clinicians, and spin-out companies to develop
new therapies led to premature clinical trials in human patients, and now the initial excitement has largely turned
to skepticism. Rather than embracing a defeatist attitude or pressing blindly ahead, I argue it is time to evaluate the
challenges encountered by regenerative medicine in the central nervous system and the progress that is being
made to solve these problems. In the twenty years since the adult brain was discovered to have an endogenous
regenerative capacity, much basic research has been done to elucidate mechanisms controlling proliferation and
cellular identity; how stem cells may be directed into neuronal lineages; genetic, pharmacological, and behavioral
interventions that modulate neurogenic activity; and the exact nature of limitations to regeneration in the adult,
aged, diseased and injured CNS. These findings should prove valuable in designing realistic clinical strategies to
improve the prospects of stem cell-based therapies. In this review, I discuss how basic research continues to play a
critical role in identifying both barriers and potential routes to regenerative therapy in the CNS.
Keywords: Regenerative medicine, Stem cell therapy, Stem cell transplant, Progenitor cell, Neurodegenerative
disease, Spinal cord injuryReview
Introduction
Great strides in stem cell biology have been made in
recent years, raising hopes for the development of indi-
vidualized regenerative therapies to reverse cell loss and
improve the function of tissues damaged by disease or
trauma. Indeed a number of clinical trials are currently
in progress to assess stem cell-based therapies for a
range of conditions. Yet the central nervous system
(CNS) poses unique problems to achieving safe, effective
regenerative therapy. The vast majority of cells in the
mammalian brain, eye, and spinal cord are produced
during embryonic development, and these tissues are
not disposed to regeneration in adult life. In short, the
production of subtype-specific neurons, followed by the
functional integration of these new cells into an existingCorrespondence: elizabeth.stoll@ncl.ac.uk
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chemical properties, remains a great technical challenge.
The CNS was in fact long thought to be incapable of
regeneration, but in the mid-1990s, cells were discovered
in the adult brain with the capacity to self-renew and
differentiate into various neuronal lineages [1,2]. The
discovery of more limited neural and glial progenitor
cells residing in the brain, spinal cord, and eye soon
followed [3,4]. Before this discovery, in 1987, a small
number of patients began receiving transplants of fetal
brain tissue to replace cells lost in Parkinson’s Disease,
with initially promising results [5]. A number of Phase I
and II trials have been undertaken in the ensuing years
to evaluate the safety and efficacy of stem cell trans-
plants for the treatment of Alzheimer’s Disease,
Huntington’s Disease, motor neuron disorders, stroke,
macular degeneration, and spinal cord injury [6,7]. Yet
these trials have largely reported modest benefits, when
results are reported at all. Disappointingly, the first
controlled clinical trial using stem cells to treat spinalis an Open Access article distributed under the terms of the Creative Commons
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halted in November 2011, and other trials for stem cell
therapies in the CNS have also been prematurely termi-
nated. Phase I/II trials for implantation of purified human
fetal neural stem cells in patients with spinal cord injury
are however currently being conducted by Stem Cells, Inc.
[7]. In addition, a number of trials are ongoing to implant
stem cells - derived from fetal brain, umbilical cord blood,
or adult bone marrow - into patients with ischemic stroke,
amyotrophic lateral sclerosis, and other neurological con-
ditions [8].
Although these therapies have not yet realized clinical
success, hope should not be lost. A great deal has been
discovered in the intervening period regarding the harnes-
sing of regenerative potential. We now have a much
greater understanding of mechanisms controlling prolifer-
ation and cellular identity; how stem cells may be directed
into neuronal lineages; genetic, pharmacological, and be-
havioral interventions that modulate neurogenic activity;
and the exact nature of limitations to regeneration in the
adult, aged, diseased and injured CNS. This basic research
has yielded both an understanding of the challenges
encountered by stem cell therapies in the central nervous
system and tools to tackle these concerns.
Below I discuss the restrictions to new neuron produc-
tion in the adult mammalian CNS, largely gained from
studying endogenous neural stem and progenitor cells
(NSPCs) in the developing and adult brain. I then describe
how neurogenic activity can be modulated in vivo to pro-
mote new neuron production. Next I highlight the prob-
lems posed to cell transplantation by the properties of the
central nervous system and how these issues are being
addressed within the field. Finally, I compare the prospects
of cell replacement therapies with other methods to restore
function to neural tissues affected by trauma or disease. In
this review, I aim to articulate how basic research con-
tinues to play a critical role in identifying both barriers and
potential routes to regenerative therapy in the CNS.
Maintaining neurogenesis: lessons from the developing
brain
Neurons are primarily produced in the mammalian brain
during a short period of embryonic development (~E10-
E14 in rodents), with the exception of cerebellum, where
the majority of neurons are born in the early postnatal
period. In fact, very few new cells are endogenously pro-
duced in the brain and spinal cord post-natally, and most
new cells produced are glia (reviewed by [9]). There are
two main areas of the adult mammalian CNS containing
stem-like cells that retain neurogenic potential: the dentate
gyrus of the hippocampus (DG), which produces new
granule neurons that may play a role in learning and mem-
ory; and the subventricular zone (SVZ), which produces
dopaminergic granule cells and GABAergic interneuronsthat migrate along the rostral migratory stream to popu-
late the olfactory bulb (reviewed by [10]). Lower levels of
neurogenesis, indicated by thymidine analog incorporation
or progenitor cell-specific protein expression, are ob-
served in the adult piriform cortex, striatum, hypothal-
amus, and amygdala [11-13]; some of these actively
dividing neural progenitors originate from cells within the
SVZ and travel along a temporal migratory stream [14].
During development, the neocortical layers are generated
in a strictly controlled spatio-temporal pattern; the deepest
layers are laid down first, and later-born neurons migrate
past early-born neurons to generate the more superficial
layers (reviewed in [15]). The process of fate restriction is
controlled by sequential expression of transcription factors;
this process is largely cell-intrinsic, as progenitors that
normally produce upper-layer neurons (layers 2/3) can-
not produce deep-layer Otx1+ neurons (layers 4–6) in
a heterochronic transplant model [16]. Most cells in the
cortex are thought to arise from the ventricular zone or
SVZ, expressing layer-specific markers as they are gen-
erated, such as Fezl in corticospinal motor neurons and
Cux2 in commissural and associative projection neurons
[17,18,19]. Inhibitory cortical neuron lineages are inde-
pendently generated, largely migrating from the medial
ganglionic eminence [20,21]. Meanwhile, medium spiny
neurons within striatum arise from the lateral ganglionic
eminences [21] and are characterized by their own unique
patterns of gene expression [22]. The range of neuronal
lineages produced by the adult brain is much more re-
stricted than the range produced during development. For
example, markers specific to neurons within superficial
cortical layers, such as Svet1 and Cux2, can be found in
the SVZ, suggesting that the adult brain can cultivate
these types of cortical neurons but not neurons within
deeper layers [18,19]. This complex array of specific gene
expression must be recapitulated in a therapeutic setting,
either prior to or post-transplantation.
Other important differences between the highly prolifer-
ative developing brain and the less plastic adult brain lie
in their respective biophysical properties. The developing
SVZ is comprised of radial glia, cells which span the
cortex and are used as scaffolding to assist migration of
new neurons to appropriate locations within cortex [23].
The elastic properties of radial glia aid the new cells on
their journey to their final location, and any disruption to
the springiness of radial glial processes harms not only
migratory activity but also neuronal maturation, as these
actions are coordinated within the differentiating cell.
Areas targeted for transplantation within the adult brain
do not possess such unique biophysical properties and
migratory paths which foster cellular integration.
Once the six layers of cortex are established, the
developmentally-active ventricular zone is exhausted and
the SVZ is separated from the lateral ventricles only by a
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These largely quiescent, GFAP +Nestin + Dcx- stem-like
cells (called B-type) intercalate into the ependymal layer
as they divide. These divisions produce a highly prolifera-
tive GFAP-Nestin + Dcx + progenitor cell (called C-type);
this progenitor in turn yields two or more lineage-
restricted, transit-amplifying, neuronal precursors (called
A-type), which migrate along the rostral migratory stream
to the olfactory bulb (reviewed in [24]). During migration,
the cells cease cell division and begin to mature into
subtype-specific neurons. The process of cell cycle length-
ening and exit is tightly coupled to lineage restriction and
neuronal differentiation [25]. This whole process allows
limited regeneration along a defined path in the adult
mammalian brain.
A similar proliferative capacity exists in the adult hippo-
campal dentate gyrus. Development of the hippocampal
formation begins at E15 in mice [26], and involves a suc-
cession of cellular matrices. The tertiary matrix is estab-
lished by P5, and remains in place for the remainder of
the lifespan. In the adult dentate gyrus, cells proliferate in
the inner granule cell layer, and migrate radially outward
as they differentiate [27]. New granule cells in hippocam-
pal dentate gyrus receive primary glutamatergic afferents
from entorhinal cortex and project axons to inhibitory
interneurons and pyramidal cells of area CA3 (including
the place cells originally characterized by O’Keefe and
Dostrovsky). Immature neurons are highly excitable, so
newly-born cells are thought to affect the dynamic proper-
ties of existing networks to which they are recruited [28].
Such circuit complexity must be kept in mind when con-
sidering cell transplantation in the CNS.
The limitations of neurogenesis in the adult brain
Although new neurons are produced in these two discrete
locations in the adult mammalian brain, neurogenesis in
both areas significantly declines across the lifespan [2].
Age-associated decreases in neurogenesis are largely due
to a depletion of the population of self-renewing cells,
which is drastically reduced at the completion of brain de-
velopment and further reduced across the lifespan [29,30].
The remaining pool of neural stem and progenitor cells in
the aged brain are characterized by a high mutational load
[31] and dysregulated cell cycle kinetics [32]. Survival of
newly-born neurons is low in adulthood and decreases
further with age, likely due to both intrinsic factors and an
inhospitable micro-environment [30].
Age-related decline in regenerative potential is a poten-
tial problem for stem cell-based therapies. With age, the
CNS environment becomes less cordial to neurons and
more conducive to glia; this is partially due to the propen-
sity of aging NSPCs to preferentially differentiate into glial
lineages over neuronal lineages [30]. However, the aging
environment also appears to play a role: the brains of agedmice are characterized by striking increases in astrocytes
and microglia [32]. In addition, chemokines present in the
aged brain negatively regulate neurogenesis [33]. Yet even
in the young adult brain, environmental cues appear to
hinder neurogenesis except in the privileged areas of SVZ
and DG. Several studies have attempted to transplant
embryonic and postnatal NSPCs into non-neurogenic
areas of the brain, with varying success in integration and
adoption of locale-specific traits [34-37]. Meanwhile, glial
progenitor cells from the spinal cord transplanted into
hippocampal DG readily acquire a granule neuron pheno-
type, demonstrating that neurogenic zones have the cap-
acity to reprogram otherwise lineage-restricted cells [38].
Unfortunately non-neurogenic areas of the adult CNS,
where cell transplants are most desirable, usually prohibit
the incorporation of new neurons. This may be less
problematic in the eye, where photoreceptors derived
from embryonic stem cells have been demonstrated to
survive and restore light responses in congenitally blind
mice [39].
The neurogenic capacity of the CNS is negatively
altered after trauma. After an injury or ischemic insult,
NSPCs proliferate uncontrollably and alter migratory
patterns, localizing to the site of injury [40]. Several
signaling cascades which boost proliferative activity have
been observed in NSPCs after middle cerebral artery
occlusion, including HIF1, Notch4, and EphrinB2 [41].
Elements within the microenvironment, such as blood
vessels and activated microglia, play a role in establish-
ing migration routes, by acting as scaffolding [42,43] and
releasing chemoattractants [40,44]. In addition, altered
migration may be easier for NSPCs in the injured brain
due to expression of matrix metalloproteinases that
digest extracellular proteins [45]. Although observations
of post-injury proliferation demonstrate the plasticity of
endogenous NSPCs, many cells produced do not survive.
The cells that do survive assist in forming scar tissue,
through which neuronal circuitry cannot readily pass. In
short, although restrictions on neurogenic activity
appear to be relaxed in the injured CNS, the net effect
of increased proliferation, decreased cell survival, and
alterations in migration is ultimately not favorable to
neuronal survival or regeneration. It is not clear that
transplantation of exogenous stem cells would benefit
tissue repair in such an inhospitable environment, par-
ticularly that observed after ischemic stroke or spinal
cord injury. Strategies have been employed to boost
axonal regeneration in the adult CNS, particularly in the
spinal cord, by altering adverse micro-environmental
components, notably Neurite Outgrowth Inhibitor (Nogo-
A), with pharmacological or antibody-based methods
[46-48]. A Phase II clinical trial evaluating the safety and
efficacy of anti-Nogo-A in treating amyotrophic lateral
sclerosis is currently ongoing, although a similar trial
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terminated [7].
Modulation of endogenous neurogenesis
A multitude of behavioral, dietary, and pharmacological
factors, as well as intracellular pathways, have demon-
strable effects on the neurogenic activity of endogenous
neural stem and progenitor cells. Studies in rodents dem-
onstrate the incredible capacity of both environmental
and intrinsic factors to regulate the proliferation, differen-
tiation, and survival of cells in the adult mammalian brain.
These factors alone are not likely to have therapeutic
benefit for humans afflicted by CNS injury or degenerative
disease, but such interventions may be useful to consider
in combination with stem cell transplants.
Environmental enrichment increases neurogenesis, pri-
marily in the adult hippocampal dentate gyrus [49,50].
The effect of environmental enrichment on hippocampal
neurogenesis is thought to be on promoting cellular sur-
vival; increased neurogenesis due to novelty appears to
have a different mechanism than that due to cardiovascu-
lar exercise because the net neurogenic effects of these
two activities together are larger than either alone [51].
The diet also influences rates of neural regeneration.
In studies of rats and mice, diets high in monounsaturated
fats, such as coconut oils, decrease neurogenesis [52],
while those high in polyunsaturated fatty acids, such as
olives, fruits, and nuts, increase adult neurogenesis [53].
Alcohol has been shown to inhibit proliferation and cause
cell death in the postnatal hippocampus [54]. Yet the
effect of alcohol, by gavage or voluntary intake, on neuro-
genic activity depends on how high the blood alcohol level
is; no study achieving blood alcohol levels under 0.18%
has demonstrated an inhibition of cell proliferation [55].
Chronic stress decreases neurogenic activity in the adult
brain, especially in females [56], while antidepressants
increase neurogenesis [57]. Stress can lead to release of
corticosterone into the bloodstream by the adrenal gland.
Activation of glucocorticoid receptors in hippocampal
NSPCs has been shown to mediate the negative effects of
corticosterone on neurogenesis [58]; adrenalectomy
reverses this effect [57]. The impact of antidepressants on
hippocampal proliferation, shown by increased labeling of
KI67 (a cell cycle marker), has been demonstrated to be
correlated with decreased plasma corticosterone [57]. Cor-
ticosterone levels therefore are considered a critical nega-
tive regulator of neurogenesis in the adult brain.
Cannabinoids have been shown to promote several
aspects of neurogenesis within the adult mouse hippo-
campus, promoting proliferation and survival, but not dif-
ferentiation, of NSPCs [59,60]. This class of molecules
include endogenously produced anandamide (AEA) and
2-arachidonylglycerol (2-AG); plant-derived cannabidiol
(CBD) and delta-9-tetrahydrocannabinol (THC); and theirsynthetic counterparts, all of which activate either or both
of the CB1 and CB2 receptors. The CB2 receptor has less
widespread expression than CB1, and is found specifically
in abundance on adult NSPCs in the SVZ and DG [60].
The CB2-specific agonist JWH-133 and the CB1/CB2 ago
nist WIN55,212-2 promote cellular proliferation in vivo;
these drugs increase KI67+ index by 23% and 31% in the
young brain, respectively, and by 350% and 600%, respect-
ively, in the aged brain, while the CB1 agonist ACEA has
no effect on neurogenesis [61]. Inhibition of fatty acid
amide hydrolase (FAAH), which degrades endocannabi-
noids, can also promote cell proliferation in vitro and
in vivo [62]. Many of these studies utilize synthetic ligands
to promote neurogenesis; one recent study of naturally
occurring compounds showed that CBD increased prolifer-
ation in the adult hippocampus, although another
plant-derived cannabinoid, THC, decreased water maze
performance and increased rotarod performance without
effects on adult hippocampal neurogenesis [63].
Studies of cortical development have proved highly
relevant to understanding the regulation of adult neuro-
genesis. Genetic knockout of Wnt3a during embryonic
development leads to complete DG ablation [64], and
mice missing other Wnt pathway elements, such as Lrp6
or Lef1, or the Wnt transcriptional target, homeobox
protein Emx2, have reductions in DG progenitors and
granule neurons [65-68]. Wnt3a appears to be crucial
for adult hippocampal neurogenesis as well, playing a
role in both proliferation and neuronal fate commitment
[69]. Other signaling pathways, such as Notch, have
primarily been investigated for roles in developmental
neurogenesis, although this factor too appears to play a
critical role in adult neurogenesis [70,71]. Changes in
both cell-intrinsic and micro-environmental factors also
affect neurogenic capacity in the aging brain, including
chromosomal loss of heterozygosity [31], increased tel-
omerase activity [72], decreased notch signaling [70],
decreased wnt signaling [69], and decreased growth fac-
tors in the microenvironment [73] – the latter possibly
due to decreased vascularity in the neurogenic niche
[74]. Cell transplantation therapies may require genetic
or epigenetic manipulation of such factors to predispose
limited proliferation, successful differentiation, and ef-
fective integration into the adult CNS.
Much discussion regarding regulation of adult neuro-
genesis centers on the broad topic of cell-intrinsic versus
cell-extrinsic influences. However distinguishing between
intracellular and micro-environmental influences on
neurogenesis is somewhat artificial. Cell cycle progression
cannot occur without the go-ahead from extrinsic sources,
such as growth factor signaling and availability of bio-
energetic substrates, and cell-extrinsic signals must be
read by a competent cell with downstream effectors
capable of translating external signals. This view, of a
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those of the population, involves the breakdown of the
concept of “self” versus “other”. Perhaps, on a biological
level, this breakdown occurred at the advent of the
multicellular organism. Cancer, then, can be understood
in terms of a re-assertion of self (the mutated cell) at the
expense of others (for example, the surrounding paren-
chyma and vasculature). Attaining a harmony between
individual cells and the other tissues is required for the
success of a multicellular organism; maintaining this
harmony is key to regenerating tissue without significantly
increasing the risk of cancer. To achieve the aims of
regenerative medicine, new cells, whether transplanted or
endogenously produced in the brain, must receive infor-
mation regarding not only what they are, but what their
role is within the community.
Some of the greatest progress in stem cell biology over
recent decades has been in simply creating a better un-
derstanding of the molecular mechanisms involved in
cellular proliferation and differentiation, through studies
of rodents and cultured cells. Promoting endogenous
neurogenesis will achieve only limited, localized neuron
production, and is therefore insufficient for therapeutic
intervention in humans, but the knowledge we have
gained from studying endogenous NSPCs will undoubt-
edly aid the field of regenerative medicine to better
guide the proliferation, fate restriction, differentiation,
survival, and functional integration of transplanted cells.
Problems [and emerging solutions] for stem cell
transplants within the central nervous system
Practical translational issues encountered by prospective
stem cell therapies targeted to the central nervous
system include designing a clinical-grade manufacturing
process, testing the therapy in an appropriate preclinical
model, selecting a relevant patient population, and mon-
itoring the transplanted cells [8]. Yet before this transla-
tional process even begins, the reluctance of the adult
central nervous system to support regeneration must be
considered in order to better devise stem cell-based
therapeutic strategies. Below is a list detailing the chal-
lenges encountered by stem cell therapies in the central
nervous system and how these concerns are being
addressed.
1. Like any transplant, rejection is a risk
Immune activity in the central nervous system is
lower than other tissues, but rejection of a
transplant is still possible. Risk can be mitigated by
collecting cells from the patients themselves and
“dedifferentiating” the cells into a pluripotent state.
Such induced pluripotent stem cells (iPSCs)
individualise therapy to reduce the incidence of
immune activity associated with rejection. HoweveriPSCs require viral-mediated transduction of host
cells to activate pluripotency genes, which have
oncogenic properties. Non-integrating viruses or use
of chemical transfection techniques avoid problems
associated with genomic insertions, but oncogene
reactivation and aberrant chromatin modification
remain a danger regardless of the method of
reprogramming. This is particularly an issue in the
low oxygen environment of the CNS, as hypoxic
conditions have been shown to re-induce pluripotency
in fate-committed cells [75].
Bone-marrow-derived mesenchymal stem cells
(MSCs) are easy to harvest from adult individuals
and were briefly thought to be promising autologous
sources of material to produce iPSCs, but they do
not differentiate well into neuronal cell types [8].
However MSCs have been shown to secrete
supportive neurotrophic factors, so co-
transplantation of this cell type may still have clin-
ical benefit. Human embryonic stem cells (ESCs) or
umbilical cord blood-derived stem cells are now
considered the best source of normal pluripotent
cells. They can be expanded in culture, directed to
differentiate into any neuronal lineage, and maintain
low chromatin abnormalities.
2. Excess proliferation can lead to cancer
Increased NSPC proliferation can be easily and
reliably achieved by knocking down tumor
suppressor pathways or activating oncogenes. But
this strategy transforms normal cells into cancerous
ones [76,77], so these options are not suitable means
of restoring cellular content in any tissue type.
Proliferative activity, particularly after
transplantation, must occur in only a limited
fashion. Some researchers have recently bypassed
the potential problem of tumor formation arising
from stem cell transplants by pre-differentiating
pluripotent (or induced pluripotent) cells to an
immature yet fate-restricted state prior to
transplantation [6,78,79]. Basic research on the
process of endogenous neuronal fate commitment
has benefited the optimization of these protocols
[24]. But pre-differentiation may not completely
preclude oncogenic risk; complex chromatin
modifications occur during embryonic development
and dedifferentiation, so even ESCs and iPSCs that
have been fate-restricted may bear hallmarks of
pluripotency within their genomes. Studies are
ongoing to compare the chromatin state of iPSCs,
ESCs, NSPCs, and cancer cells to better understand
and manage the risk of oncogenic transformation.
3. Making a neuron to order is a difficult task
The developing brain is capable of producing an
astounding variety of neuronal subtypes. Yet the
Stoll Molecular and Cellular Therapies 2014, 2:12 Page 6 of 9
http://www.molcelltherapies.com/content/2/1/12adult brain is more limited, due to a number of
molecular and biophysical characteristics. It is an
extraordinarily difficult task to recapitulate even a
small aspect of the developmental program in the
adult or aged brain. Much progress has been made
in cell cultures: a number of protocols have been
designed to optimize large-scale production of
particular neuronal subtypes [78,79]. The desired
cell type or mix of cell types can be further enriched
by sorting for surface antigens (antibody-based selec-
tion) or with fluorescent reporters (promoter/enhan-
cer-based selection). But even if cells take on the
appropriate anatomical characteristics and
immunohistochemical markers, they will not
necessarily function as expected if transplanted into
the adult mammalian brain, eye, or spinal cord. When
cells are reprogrammed, we must ask whether these
cells are ‘true’ subtype-specific neurons – with the
expected electrophysiological and epigenetic properties,
the proper neurotransmitter phenotype and the
required complement of ion channels. This issue is
difficult enough when one cell type is demanded, such
as dopaminergic neurons to replace those lost in
Parkinson’s Disease, but the problem becomes even
more challenging when more than one cell type
may be needed to regenerate the tissue and reduce
or bypass normal scar formation, as in the case of
spinal cord injury.
4. Controlling the influence of the micro-environment
is near impossible
The CNS generates neurons during a developmental
period and does not prefer to do so later on. The
adult brain microenvironment in fact encourages glial
differentiation. Even if cells are pre-differentiated
toward a neuronal fate, the transplant itself could
cause sufficient injury to initiate glial scarring and
inhibit the survival and integration of newly
transplanted neurons. There is great interest in limit-
ing or guiding the effects of the CNS environment on
the transplanted cell [46-48]. However, since our
understanding of the complex milieu of the adult CNS
is limited, the best strategy may be to imitate structural
elements of it. Establishing a conducive local
microenvironment by combining transplanted cells
with a simulated extracellular matrix may promote
functional reorganization of the tissue [80], while
introducing microgravity prior to transplantation
appears to aid survival and integration of the cells [81].
In addition, neurotrophic factors injected along with
the cells or secreted by the transplanted cells may
work to provide a favorable environment for tissue
regeneration [82]. These therapies are currently being
evaluated separately and in combination with stem
cell-based therapies.5. The fate of most transplanted cells is death
Pioneering clinical transplantation studies endowed
human Parkinson’s Disease patients with tissue
grafts from up to seven fetal brains, a source and
quantity that is both controversial and practically
unrealistic. Cell survival was estimated to be only
5% in histopathological assessment eighteen months
post-transplantation [5]. More recently, monkeys
with MPTP lesions were injected with 300,000-
600,000 ESCs pre-differentiated to a dopaminergic
neuron state, but less than 1% of these transplanted
cells remained after three months [83]. In both
cases, lasting clinical benefit was reported despite
the low cell survival rate, suggesting that few cells
may actually need to survive in order to provide
functional recovery.
6. Forging connections in a new place can be hard
Full neuronal differentiation in vitro is likely to
preclude integration into the brain circuitry, because
forging connections with other neurons is a critical
part of neuronal maturation and cell survival. Much
research has gone toward exploring intermediate
states of differentiation, to manufacture implantable
cells that are fate-restricted yet still ready to forge
an identity within the neuronal circuitry. Self-
assembling polymers provide a three-dimensional
framework to aid network integration; introducing
elements of the extracellular matrix may also help to
cultivate nearby vasculature for metabolic support
[80]. Circuit integration can be monitored by
combining transplants with optogenetic stimulation,
a process which may also prove useful in enhancing
activity-dependent survival of newly transplanted
cells [84]. In some cases however, even successful
cell survival and integration of implanted cells does
not guarantee functional recovery after injury [85].
Conversely, therapeutic benefit has been observed
after cellular transplantation in the adult CNS even
without any evidence of axonal outgrowth or
improved functional connectivity, due in part to
neurotrophin secretion by the transplanted cells
[82]. These studies support the idea that successful
survival and integration of transplanted cells into
existing neural networks may not always be
necessary to achieve some clinical benefit from stem
cell therapies. Indeed, if some axons are spared after
spinal cord injury, pro-survival and remyelination
cues may be sufficient to improve recovery without
the need for cell replacement [86].
7. Immature neuronal excitability could lead to
network dysfunction
The addition of new cells, particularly immature
excitatory neurons, which fire action potentials in
response to the (normally inhibitory)
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neural network activity or confer novel
characteristics on CNS circuitry [24]. This area of
electrophysiological research is underexplored, and
the risks associated with this issue are understudied
in relevant preclinical models. However, the
transplantation of inhibitory neuron precursors has
notably been shown to decrease epileptogenesis [87].Regenerative medicine: a promising route?
Although some studies have shown encouraging results, a
number of challenges remain to making cellular trans-
plantation a realistic clinical treatment for neurological
disorders. If stem cell therapies alone do not prove to have
strong, lasting clinical benefit, combination therapies may
hold promise. Cell transplantations may be supplemented
by optogenetic or electrical stimulation to promote axonal
remodeling. Cells might be transplanted alongside growth
factors, anti-anti-growth factors, or a simulated extracellu-
lar matrix. Moreover, autologous cells may be engineered
prior to transplantation to produce neurotrophic factors
or even to correct a genetic deficiency, in order to support
the function of an existing neural population rather than
replacing it entirely.
An alternative strategy to regenerative medicine is to by-
pass damaged tissues completely using a neural prosthetic
device or direct electrical stimulation. For example, signals
from the motor cortex can be translated directly to the
muscles or to a robotic arm after spinal cord injury or
brainstem stroke using a brain-machine interface to
achieve functional motor control [88]. And published re-
ports demonstrate that deep-brain stimulation reliably
and effectively controls symptoms of dystonia in patients
with Parkinson’s Disease [89]. Stem cell-based therapies in
the CNS have achieved nothing near these successes. It is
important to note that the therapeutic potential of brain-
machine interfaces and deep-brain stimulation was only
realized after decades of basic research into the anatomy
and physiology of underlying neural circuitry [90]; stem
cell-based methods for treating neurological disorders
must similarly comprehend the inherent properties of the
CNS before attempting to fix it.
Conclusions
Despite all of the challenges faced by stem cell therapies
within the central nervous system, a number of leaps
forward have been made that bring the promise of such
treatments ever closer. Yet the eagerness for new therapies
must always be tempered by careful assessment of the
preclinical data and an understanding of the benefits and
limitations of regeneration in the adult CNS. To achieve
clinical therapies, we will need to address the obstacles
posed by the adult CNS: namely risks associated with
rejection, overproliferation, glial scarring, neuronal subtypespecification, micro-environmental limitations, and diffi-
culties in cell survival and circuit integration.
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